Novo Nordisk Collaborates With Omega Therapeutics And Cellarity For Obesity, Metabolic Dysfunction-associated Steatohepatitis, Respectively; Novo Nordisk Will Reimburse R&D Costs, Each Company And Flagship's Pioneering Medicines Will Receive Up To $532M

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!